NCT01053520CompletedPhase 1
Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Abbott
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Assess the oral bioavailability of Formulation B1 and Formulation B2 via pharmacokinetic measurements relative to Formulation A .
Study Overview
Brief Summary
This is a Phase 1, randomized, open-label, single center, three period crossover study to determine the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 12 healthy female subjects will be enrolled in this study.
Detailed Description
This is a Phase 1, randomized, open-label, single center, three period crossover study to determine the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 12 healthy female subjects will be enrolled in this study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Female and age is between 18 and 55 years, inclusive.
- •Must be surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), postmenopausal (for at least 2 years), or practicing at least one acceptable method of birth control.
- •Must have negative results for pregnancy tests performed at Screening on a urine sample obtained within 28 days prior to initial study drug administration, and on Period 1 Day -1 on a serum specimen.
- •Body Mass Index (BMI) is 18 to 29, inclusive. BMI is calculated as weight in kg divided by the square of height measured in meters.
- •Must have adequate bone marrow function per local laboratory reference range (Platelets >/= lower limit of normal range, ANC >/= lower limit of normal range)
- •A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).
- •Must voluntarily sign and date each informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any study-specific procedures.
Exclusion Criteria
- •History of significant sensitivity to any drug
- •History of drug or alcohol abuse w/i 6 months or currently receiving Disulfiram
- •Known/suspected history of HIV
- •History of or active medical condition(s) or surgical procedure(s) that might affect GI motility, pH, absorption
- •History of thrombocytopenic associated bleeding w/i 1 year prior to ABT-263
- •Significant history of cardiovascular disease (e.g., MI, thrombotic or thromboembolic event in last 6 months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, respiratory (except mild asthma), gastrointestinal, hematologic, or hepatic disease or diabetes, cancer, epilepsy, or seizures that in the opinion of the PI would adversely affect her participating in the study.
- •Underlying condition predisposing to bleeding or currently exhibits signs of clinically significant bleeding or active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
- •Positive result for drugs of abuse, alcohol, cotinine, hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab).
- •Consumed alcohol, grapefruit or starfruit product, or Seville oranges w/i 3 days prior to ABT-263
- •Received aspirin, anticoagulation therapy, or any drugs or herbal supplements that affect platelet function w/i 7 days prior to/during ABT-263
- •Used any medications, vitamins, or herbal supplements (except contraceptives) w/i 14 days prior to ABT-263
- •Received any drug by injection or biologic agent w/i 30 days prior to ABT-263 (except parenteral hormonal contraceptives)
- •Used known inhibitors or inducers CYP3A w/i 1 month prior to ABT-263; Received any investigational product w/i 6 weeks prior to ABT-263
- •Used tobacco or nicotine-products w/i 6 months prior to ABT-263
- •Pregnant or breastfeeding
- •Donation or loss of >/=550 mL blood or received transfusion of blood product w/i 8 weeks prior ABT-263
- •Currently enrolled in another study.
- •The PI decides the subject is unsuitable to receive ABT-263.
Arms & Interventions
Sequence I
Experimental
Intervention: ABT-263 (Drug)
Sequence II
Experimental
Intervention: ABT-263 (Drug)
Sequence III
Experimental
Intervention: ABT-263 (Drug)
Outcomes
Primary Outcomes
Assess the oral bioavailability of Formulation B1 and Formulation B2 via pharmacokinetic measurements relative to Formulation A .
Time Frame: Each formulation assessed via 13 PK timepoints over 4 days
Secondary Outcomes
- Secondary outcome measures include adverse event monitoring, vital signs, physical examinations, ECGs, and laboratory assessments including pharmacogenetics.(Assessed over the confinement period of 17 days of study duration)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy SubjectsRelative BioavailabilityNCT02052349AbbVie12
Completed
Phase 1
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy AdultsChronic Hepatitis BNCT04083716Assembly Biosciences15
Completed
Phase 1
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With CancerSolid TumorNCT00888108Abbott41
Completed
Phase 1
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015KBioavailability of ASP015KPharmacokinetics of ASP015KHealthy SubjectsNCT01486017Astellas Pharma Inc30
Completed
Phase 1
A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male VolunteersHealthyNCT01157000Johnson & Johnson Pharmaceutical Research & Development, L.L.C.9